title: Recurrent fallopian tube carcinoma: TP53 mutation and clinical course.
abstract: Primary fallopian tube carcinoma is a rare, aggressive gynecological cancer; little is known about its cause. Previous studies have indicated that p53 immunopositivity is correlated with short-term survival in primary fallopian tube carcinoma. We examined p53 and p21/WAF1 immunostaining and TP53 mutation in exons 5 to 8 by single-stranded conformation polymorphism and constant denaturant gel electrophoresis in nine cases of primary fallopian tube carcinoma and their metastases/recurrences from patients who survived for between a few months and more than 20 years after diagnosis. We found that 1.) p53 immunopositivity without detectable p21/WAF1 immunostaining did not correlate with TP53 mutations in the conserved domains; 2.) mutations in TP53 occurred in two metastases/recurrences but not in their corresponding primary tumors; 3.) in two cancers, a TP53 mutation was observed in the primary tumor but not in the metastases/recurrences; 4.) constant denaturant gel electrophoresis seems to be more sensitive than single-stranded conformation polymorphism in detecting TP53 mutations; and 5.) in the nine cases studied, p53 immunoreactivity and/or TP53 mutation analysis did not correlate with tumor progression, survival, or response to treatment.
authors.affiliation: Department of Gynaecological Oncology, Karolinska Hospital and Institutet, Stockholm, Sweden.
authors.forename: A C
authors.initials: AC
authors.lastname: Hellström
authors.forename: H
authors.initials: H
authors.lastname: Blegen
authors.forename: M
authors.initials: M
authors.lastname: Malec
authors.forename: C
authors.initials: C
authors.lastname: Silfverswärd
authors.forename: S
authors.initials: S
authors.lastname: Lystad
authors.forename: A L
authors.initials: AL
authors.lastname: Børresen-Dale
authors.forename: G
authors.initials: G
authors.lastname: Auer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000032:analysis; D004252:DNA Mutational Analysis; D005091:Exons; D005185:Fallopian Tube Neoplasms / Q000235:genetics* / Q000601:surgery / Q000628:therapy; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D018807:Polymorphism, Single-Stranded Conformational; D011878:Radiotherapy; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016159:Tumor Suppressor Protein p53